Literature DB >> 16131484

Serum microarrays for large scale screening of protein levels.

Magdalena Janzi1, Jenny Odling, Qiang Pan-Hammarström, Mårtenn Sundberg, Joakim Lundeberg, Mathias Uhlén, Lennart Hammarström, Peter Nilsson.   

Abstract

There is a great need for comprehensive proteomic analysis of large patient cohorts of plasma and serum samples to identify biomarkers of human diseases. Here we describe a new antibody-based proteomic approach involving a reverse array format where serum samples are spotted on a microarray. This enables all samples to be screened for their content of a certain serum protein in a single experiment using target-recognizing antibodies and fluorescently labeled secondary antibodies. The procedure is illustrated with the analysis of the IgA levels in 2009 spotted serum samples, and the data are compared with clinical routine measurements. The results suggest that it is possible to simultaneously screen thousands of complex clinical serum samples for their content of the relative amount of specific serum proteins of clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16131484     DOI: 10.1074/mcp.M500213-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  22 in total

Review 1.  Immunoinformatics: an integrated scenario.

Authors:  Namrata Tomar; Rajat K De
Journal:  Immunology       Date:  2010-08-16       Impact factor: 7.397

2.  Biomarker discovery and clinical proteomics.

Authors:  Jerzy Silberring; Pawel Ciborowski
Journal:  Trends Analyt Chem       Date:  2010-02-01       Impact factor: 12.296

Review 3.  Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications.

Authors:  Wei-Jun Qian; Jon M Jacobs; Tao Liu; David G Camp; Richard D Smith
Journal:  Mol Cell Proteomics       Date:  2006-08-03       Impact factor: 5.911

Review 4.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

5.  The higher frequency of IgA deficiency among Swedish twins is not explained by HLA haplotypes.

Authors:  M Frankowiack; R-M Kovanen; G A Repasky; C K Lim; C Song; N L Pedersen; L Hammarström
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

Review 6.  Histo-proteomic profiling of formalin-fixed, paraffin-embedded tissue.

Authors:  Kant M Matsuda; Joon-Yong Chung; Stephen M Hewitt
Journal:  Expert Rev Proteomics       Date:  2010-04       Impact factor: 3.940

Review 7.  Targeted proteomic strategy for clinical biomarker discovery.

Authors:  Ralph Schiess; Bernd Wollscheid; Ruedi Aebersold
Journal:  Mol Oncol       Date:  2008-12-11       Impact factor: 6.603

8.  Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer.

Authors:  Tobias Grote; Doris R Siwak; Herbert A Fritsche; Corwin Joy; Gordon B Mills; Diane Simeone; David C Whitcomb; Craig D Logsdon
Journal:  Proteomics       Date:  2008-08       Impact factor: 3.984

9.  Covalent immobilization of p-selectin enhances cell rolling.

Authors:  Seungpyo Hong; Dooyoung Lee; Huanan Zhang; Jennifer Q Zhang; Jennifer N Resvick; Ali Khademhosseini; Michael R King; Robert Langer; Jeffrey M Karp
Journal:  Langmuir       Date:  2007-10-20       Impact factor: 3.882

10.  Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker.

Authors:  Adriana Aguilar-Mahecha; Christiane Cantin; Maureen O'Connor-McCourt; Andre Nantel; Mark Basik
Journal:  Proteome Sci       Date:  2009-04-06       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.